The data and the market has spoken on HUGE volume, PER has no drugs AT ALL . How after 20 years the drug turned out to be so inert and yet get to this stage of testing and investment is of course a reasonable question.
If you see the AGM presentation they do seem to discuss a back-up plan if results aren't great, but looking at Garners post results webinar, you get the feeling results as bad as this were not in the thinking. Do they really want to go down the MS route when the drug is so inert ?
The next step to watch is obviously for anyone leaving the company, although at $8 million mkt cap the team is already being valued as if it is gone.
PER Price at posting:
0.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)